

Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081
Fax: 040 30211602
Email: neuland@neulandlabs.com
www.neulandlabs.com

NEULAND LABORATORIES LIMITED
Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113,
Road No. 2, Banjara Hills, Hyderabad - 500034
STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2019

(Amount in lakhs of ₹, unless otherwise stated)

Sl. No.	Particulars	STANDALONE					CONSOLIDATED	
		Quarter Ended		Year Ended			Year Ended	
		31.03.2019 (Audited) (Note 4)	31.12.2018 (Unaudited)	31.03.2018 (Audited) (Note 5)	31.03.2019 (Audited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
1	Revenue							
	(a) Revenue from operations (Refer Note 7)	17,266.17	17,146.95	16,022.62	66,682.95	52,916.15	66,682.95	52,916.15
	(b) Other income	133.41	40.53	29.05	349.16	453.45	349.20	453.48
	Total Income	17,399.58	17,187.48	16,051.67	67,032.11	53,369.60	67,032.15	53,369.63
2	Expenses							
	(a) Cost of materials consumed	8,897.91	8,609.38	7,951.45	36,044.19	28,109.42	36,044.19	28,109.42
	(b) Excise duty (Refer Note 7)	-	-	-	-	175.47	-	175.47
	(c) Changes in inventories of finished goods and work-in-progress	208.93	712.48	73.82	580.08	(4,272.41)	580.08	(4,272.41)
	(d) Employee benefits expense	2,734.29	2,680.80	2,249.59	10,447.48	9,572.79	11,045.60	10,298.62
	(e) Finance costs	471.09	299.90	487.80	1,566.31	1,892.13	1,566.31	1,892.84
	(f) Depreciation and amortisation expense	693.07	735.24	560.97	2,586.02	2,210.35	2,586.26	2,210.35
	(g) Manufacturing expenses	2,028.02	1,953.21	2,013.10	7,691.36	8,149.10	7,691.36	8,149.10
	(h) Other expenses	1,557.22	1,606.90	1,855.75	6,133.17	6,178.72	5,484.62	5,412.80
	Total expenses	16,590.53	16,597.91	15,192.48	65,048.61	52,015.57	64,998.42	51,976.19
3	Profit before tax (1-2)	809.05	589.57	859.19	1,983.50	1,354.03	2,033.73	1,393.44
4	Tax expense							
	(a) Current tax	205.08	156.47	86.22	544.35	422.92	556.96	427.00
	(b) Deferred tax benefit	(68.98)	(26.90)	(32.32)	(175.19)	(249.70)	(167.39)	(239.85)
5	Profit for the period / year (3-4)	672.95	460.00	805.29	1,614.34	1,180.81	1,644.16	1,206.29
6	Other comprehensive income (net of taxes)							
	(a) Items that will not be reclassified to profit or loss							
	Re-measurement gains/(losses) on defined benefit plans	(85.02)	36.04	52.77	23.08	27.28	23.08	27.28
	Equity instruments through other comprehensive income	0.95	0.58	1.70	(0.10)	1.70	(0.09)	1.70
	Tax on items that will not be reclassified to profit or loss	29.42	(12.47)	(18.26)	(7.99)	(9.44)	(7.99)	(9.44)
	(b) Items to be reclassified to profit or loss							
	Exchange differences in translating the financial statements of a foreign operations						16.77	16.77
	Total comprehensive income	618.30	484.15	841.50	1,629.33	1,200.35	1,675.93	1,242.60
7	Paid-up Equity Share Capital (Face value - ₹10 each)	1,290.05	1,290.05	895.49	1,290.05	895.49	1,290.05	895.49
8	Other equity				68,267.87	23,497.51	68,640.74	23,823.80
9	Equity suspense account				-	31,084.99	-	31,084.99
10	Earnings Per Share (of ₹10 each) (In absolute ₹ terms)							
	(a) Basic (refer note 6)	5.25	3.59	7.22	12.83	10.59	13.06	10.81
	(b) Diluted (refer note 6)	5.25	3.59	7.22	12.83	10.59	13.06	10.81
	See accompanying notes to the financial results							





NOTES:

- 1 The financial results for the quarter and year ended 31 March 2019, have been reviewed by the Audit Committee, approved by the Board of Directors at their meeting held on 16 May 2019.
- 2 The operations of the Company are predominantly related to the manufacture of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 "Operating Segments".
- 3 The Company has adopted Ind AS 115 - Revenue from Contracts with Customers, using modified retrospective application method with effect from 1 April 2018 and accordingly these financial results are prepared in accordance with the recognition and measurement principles laid down in Ind AS 115. Also, the application of Ind AS 115 did not have any significant impact on recognition and measurement of revenue and related items in the financial results of the Company.
- 4 The figures of the quarter ended 31 March 2019 are balancing figures between audited figure in respect of the full financial year ended 31 March 2019 and the published year to date figures upto the quarter ended 31 December 2018, which were subjected to limited review by the statutory auditors.
- 5 Pursuant to the Scheme of Amalgamation and Arrangement ("the Scheme") duly approved by the National Company Law Tribunal, Hyderabad Bench vide their order dated 21 March 2018, Neuland Health Sciences Private Limited ("NHSPL") and Neuland Pharma Research Private Limited ("NPRPL") (together referred to as "Transferor Companies"), were merged with Neuland Laboratories Limited ("NLL"). In view of the aforesaid Scheme being effective from 1 April 2016, management has carried out necessary adjustments to all the unaudited and reviewed financial results of the Company published in accordance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarters and year to date periods commencing from 1 April 2016 to December 2017. Adjustment to such published financial results have been made on the basis of separate results of the Company and the management prepared unaudited/unreviewed financial results of the erstwhile transferor companies for the relevant periods.

Accordingly, the figures for the quarter ended 31 March 2018 being the balancing figure between the audited figures in respect of the full financial year ended 31 March 2018 and the unaudited year to date figures up to the nine months ended 31 December 2017 is arrived on the basis explained above.
- 6 During the period ended 30 June 2018, 6,861,243 equity shares of ₹10 each have been allotted to the shareholders of the Transferor Companies pursuant to the Scheme after cancellation of cross holding of 4,590,608 equity shares and 499,965 equity shares in NLL and NPRPL respectively held by NHSPL. Net increase in the paid-up share capital on this account (i.e., 2,270,635 equity share of ₹10 each) has been considered from the beginning of the financial years for the purpose of computation of basic and diluted earnings per share for all the presented periods. Further, the EPS for quarters has not been annualised.
- 7 Post implementation of Goods and Services Tax ("GST") in India with effect from 1 July 2017, revenues are disclosed net of GST. Revenues for the period prior to 1 July 2017 includes excise duty which is now subsumed in the GST. Accordingly, revenues for the year ended 31 March 2019 is not comparable with those for the year ended 31 March 2018.
- 8 The Consolidated Financial Results include results for the year ended 31 March 2019 of the following subsidiaries:
(a) Neuland Laboratories Inc., USA;
(b) Neuland Laboratories KK., Japan.
- 9 The Board of Directors had at the meeting held on 16 May 2019, declared a dividend of ₹1.20/- per equity share of face value of ₹10/- each, subject to the approval of the shareholders in the ensuing Annual General Meeting.

Place: Hyderabad
Date: 16 May 2019



By Order of the Board
For Neuland Laboratories Limited

Dr. D R Rao
Chairman and Managing Director
(DIN: 00107737)

NEULAND LABORATORIES LIMITED
Statement of Assets and Liabilities

(Amount in lakhs of ₹, unless otherwise stated)

	Standalone		Consolidated	
	31 March 2019	31 March 2018	31 March 2019	31 March 2018
	(Audited)		(Audited)	
ASSETS				
Non-current assets				
Property, plant and equipment	23,040.62	16,376.23	23,041.81	16,376.23
Capital work in progress	10,447.37	12,609.45	10,447.37	12,609.45
Investment property	2,981.39	2,981.39	2,981.39	2,981.39
Goodwill	27,946.10	27,946.10	27,946.10	27,946.10
Other intangible assets	180.70	178.44	180.70	178.44
Financial assets				
(i) Investments	55.74	55.84	39.92	40.02
(ii) Loans	309.68	302.26	312.63	304.94
Non-current tax assets	888.02	931.56	891.06	943.29
Other non-current assets	1,846.82	1,040.23	1,846.82	1,040.23
Total non-current assets	67,696.44	62,421.50	67,687.80	62,420.09
Current assets				
Inventories	19,265.42	17,508.79	19,265.42	17,508.79
Financial Assets				
(i) Investments	750.00	750.00	750.00	750.00
(ii) Trade receivables	16,401.97	19,392.27	16,401.97	19,392.27
(iii) Cash and cash equivalents	744.22	308.43	793.77	328.79
(iii) Other bank balances	2,990.67	1,396.81	2,990.67	1,396.81
(v) Other financial assets	552.04	395.64	552.04	395.64
Other current assets	4,588.88	4,920.98	4,593.57	4,946.99
Total current assets	45,293.20	44,672.92	45,347.44	44,719.29
Total assets	112,989.64	107,094.42	113,035.24	107,139.38
EQUITY AND LIABILITIES				
Equity				
Equity share capital	1,290.05	895.49	1,290.05	895.49
Other equity	68,267.86	23,497.52	68,640.73	23,823.80
Equity suspense account	-	31,084.99	-	31,084.99
Total equity	69,557.91	55,478.00	69,930.78	55,804.28
Liabilities				
Non-current liabilities				
Financial liabilities				
(i) Borrowings	6,071.55	10,348.82	6,071.54	10,348.82
Provisions	1,174.02	987.00	1,191.33	987.00
Deferred tax liabilities	1,039.25	1,214.43	1,115.45	1,278.77
Other non-current liabilities	2,028.00	2,028.00	2,028.00	2,028.00
Total non-current liabilities	10,312.82	14,578.25	10,406.32	14,642.59
Current liabilities				
Financial liabilities				
(i) Borrowings	14,905.83	19,920.26	14,905.83	19,920.26
(ii) Trade payables				
- total outstanding dues of micro and small enterprises	122.03	26.23	122.03	26.23
- total outstanding dues of creditors other than micro and small enterprises	12,539.29	12,875.00	12,106.99	12,403.26
(iii) Other financial liabilities	3,726.14	2,950.65	3,731.20	3,013.64
Other current liabilities	1,745.97	1,106.57	1,752.44	1,169.66
Provisions	79.65	159.46	79.65	159.46
Total current liabilities	33,118.91	37,038.17	32,698.14	36,692.51
Total equity and liabilities	112,989.64	107,094.42	113,035.24	107,139.38

